CN117255781A - 氯苯唑酸的固态形式及其制备方法 - Google Patents

氯苯唑酸的固态形式及其制备方法 Download PDF

Info

Publication number
CN117255781A
CN117255781A CN202280030391.4A CN202280030391A CN117255781A CN 117255781 A CN117255781 A CN 117255781A CN 202280030391 A CN202280030391 A CN 202280030391A CN 117255781 A CN117255781 A CN 117255781A
Authority
CN
China
Prior art keywords
benzoxazole
dichlorophenyl
carboxylic acid
crystalline form
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280030391.4A
Other languages
English (en)
Chinese (zh)
Inventor
G·巴雷卡
L·卡科内
P·帕拉维迪诺
D·彭戈
M·扎皮耶里
黄立明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthetic Chemistry Co ltd
Original Assignee
Synthetic Chemistry Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthetic Chemistry Co ltd filed Critical Synthetic Chemistry Co ltd
Publication of CN117255781A publication Critical patent/CN117255781A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
CN202280030391.4A 2021-04-26 2022-04-22 氯苯唑酸的固态形式及其制备方法 Pending CN117255781A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382362.8 2021-04-26
EP21382362.8A EP4083027A1 (en) 2021-04-26 2021-04-26 A solid state form of tafamidis and a process for its preparation
PCT/EP2022/060716 WO2022229026A1 (en) 2021-04-26 2022-04-22 A solid state form of tafamidis and a process for its preparation

Publications (1)

Publication Number Publication Date
CN117255781A true CN117255781A (zh) 2023-12-19

Family

ID=75746555

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280030391.4A Pending CN117255781A (zh) 2021-04-26 2022-04-22 氯苯唑酸的固态形式及其制备方法

Country Status (8)

Country Link
US (1) US20240208915A1 (https=)
EP (2) EP4083027A1 (https=)
JP (1) JP2024515770A (https=)
CN (1) CN117255781A (https=)
BR (1) BR112023022116A2 (https=)
CA (1) CA3216325A1 (https=)
MX (1) MX2023012460A (https=)
WO (1) WO2022229026A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250042864A1 (en) * 2021-11-17 2025-02-06 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102844290A (zh) * 2010-04-21 2012-12-26 奇斯药制品公司 用于治疗转甲状腺素蛋白淀粉样变性的1-(2-氟联苯-4-基)-烷基羧酸衍生物
CN106715405A (zh) * 2014-09-08 2017-05-24 辉瑞公司 6‑羧基‑2‑(3,5‑二氯苯基)苯并噁唑的结晶固体形式
CN113993853A (zh) * 2019-05-16 2022-01-28 梯瓦制药国际有限责任公司 氯苯唑酸及其盐的固态形式

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800237C (en) 2002-12-19 2016-05-17 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
RU2586330C2 (ru) 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
US20220251052A1 (en) * 2019-07-04 2022-08-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
WO2021019448A1 (en) 2019-08-01 2021-02-04 Honour (R&D) Process for the preparation of transthyretin dissociation inhibitor
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
US12522573B2 (en) * 2020-10-19 2026-01-13 Alivus Life Sciences Limited Process for preparation of tafamidis and salts thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102844290A (zh) * 2010-04-21 2012-12-26 奇斯药制品公司 用于治疗转甲状腺素蛋白淀粉样变性的1-(2-氟联苯-4-基)-烷基羧酸衍生物
CN106715405A (zh) * 2014-09-08 2017-05-24 辉瑞公司 6‑羧基‑2‑(3,5‑二氯苯基)苯并噁唑的结晶固体形式
CN113993853A (zh) * 2019-05-16 2022-01-28 梯瓦制药国际有限责任公司 氯苯唑酸及其盐的固态形式

Also Published As

Publication number Publication date
US20240208915A1 (en) 2024-06-27
WO2022229026A1 (en) 2022-11-03
BR112023022116A2 (pt) 2024-01-09
EP4083027A1 (en) 2022-11-02
EP4330237A1 (en) 2024-03-06
JP2024515770A (ja) 2024-04-10
MX2023012460A (es) 2023-12-14
CA3216325A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
CN114605406B (zh) Amg510化合物的晶型及其制备方法和用途
JP5889275B2 (ja) ラルテグラビル塩およびその結晶形
US20200247753A1 (en) Polymorphs and co-crystals of roxadustat
US8933114B2 (en) Polymorphic forms of asenapine maleate and processes for their preparation
US20090076272A1 (en) Polymorphs of eszopiclone malate
EP1699773A2 (en) Processes for preparation of crystalline mycophenolate sodium
CN117255781A (zh) 氯苯唑酸的固态形式及其制备方法
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
US8946441B2 (en) Polymorphs of an active pharmaceutical ingredient
CN114478512A (zh) 一种酸的晶型及其制备方法
JP2016504364A (ja) コビシスタット塩
JP5847567B2 (ja) 活性医薬成分の結晶形態
EP2397473A1 (en) A stable highly crystalline anacetrapib
JP2020536940A (ja) エダラボン塩
US20260070928A1 (en) Novel crystalline forms of (s)-7-oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2h-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide and co-crystal forms thereof
EP3075724B1 (en) Solid form of agomelatine
US20240150282A1 (en) Novel crystalline compound of siponimod hemifumarate
WO2026018214A1 (en) Solid state forms of tinlarebant and process for preparation thereof
WO2024102925A1 (en) Crystalline forms of a farnesoid x receptor agonist
TW202333694A (zh) 稠環衍生物的晶型、其製備方法及其應用
TW202515536A (zh) 以解析方法來製備富含鏡像異構型態的（ｓ）－６－氯－２，３，４，９－四氫－１ｈ－咔唑－甲醯胺
KR100749219B1 (ko) 신규한 로지글리타존 옥살산염, 이의 제조방법, 및 이를포함하는 약제학적 조성물
CN121399108A (zh) Baxdrostat的晶型及其制备方法和用途
CN121293119A (zh) 沙库巴曲或其盐与阿齐沙坦或其盐的共晶
CN114591211A (zh) 一种酰胺化合物的共晶及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination